Moderna CEO Eyes European Market to Hit 2028 Breakeven Goals -- Market Talk

Dow Jones

Jan 14

1113 ET - Moderna is eyeing international markets, especially in Europe, as the company works to hit a breakeven point in 2028, CEO Stéphane Bancel said Monday at the JPMorgan Healthcare Conference. Bancel points out that Pfizer's partnership with the European Union expires at the end of the year, giving Moderna a window to capture a share of the high-volume Covid-19 vaccine market in Europe. If Moderna is able to get European approval for a flu-plus-Covid combo vaccine in 2026, that would also be a positive catalyst for sales growth, he says. The company is also looking to build on partnerships with governments in the United Kingdom, Canada, and Brazil as it looks to drive geographic diversity, Bancel says.(elias.schisgall@wsj.com)

(END) Dow Jones Newswires

January 13, 2026 11:13 ET (16:13 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603636548"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603636548\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603636548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 00:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603636548","market":"hk","top_or_hot":-1,"title":"Moderna CEO Eyes European Market to Hit 2028 Breakeven Goals -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1113 ET - <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> is eyeing international markets, especially in Europe, as the company works to hit a breakeven point in 2028, CEO Stéphane Bancel said Monday at the JPMorgan Healthcare Conference. Bancel points out that Pfizer's partnership with the European Union expires at the end of the year, giving Moderna a window to capture a share of the high-volume Covid-19 vaccine market in Europe. If Moderna is able to get European approval for a flu-plus-Covid combo vaccine in 2026, that would also be a positive catalyst for sales growth, he says. The company is also looking to build on partnerships with governments in the United Kingdom, Canada, and Brazil as it looks to drive geographic diversity, Bancel says.(elias.schisgall@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 11:13 ET (16:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO Eyes European Market to Hit 2028 Breakeven Goals -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO Eyes European Market to Hit 2028 Breakeven Goals -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 00:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1113 ET - <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> is eyeing international markets, especially in Europe, as the company works to hit a breakeven point in 2028, CEO Stéphane Bancel said Monday at the JPMorgan Healthcare Conference. Bancel points out that Pfizer's partnership with the European Union expires at the end of the year, giving Moderna a window to capture a share of the high-volume Covid-19 vaccine market in Europe. If Moderna is able to get European approval for a flu-plus-Covid combo vaccine in 2026, that would also be a positive catalyst for sales growth, he says. The company is also looking to build on partnerships with governments in the United Kingdom, Canada, and Brazil as it looks to drive geographic diversity, Bancel says.(elias.schisgall@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 11:13 ET (16:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603636548","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603636548","pubTimestamp":1768320780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1113 ET - Moderna is eyeing international markets, especially in Europe, as the company works to hit a breakeven point in 2028, CEO Stéphane Bancel said Monday at the JPMorgan Healthcare Conference. Bancel points out that Pfizer's partnership with the European Union expires at the end of the year, giving Moderna a window to capture a share of the high-volume Covid-19 vaccine market in Europe. If Moderna is able to get European approval for a flu-plus-Covid combo vaccine in 2026, that would also be a positive catalyst for sales growth, he says. The company is also looking to build on partnerships with governments in the United Kingdom, Canada, and Brazil as it looks to drive geographic diversity, Bancel says.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4588":"碎股","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","MRNA":"Moderna, Inc.","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4501":"段永平概念","BK4551":"寇图资本持仓"},"translate_title":"Moderna首席执行官着眼于欧洲市场实现2028年盈亏平衡目标——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"1113 ET - Moderna is eyeing international markets, especially in Europe, as the company works to hit a breakeven point in 2028, CEO Stéphane Bancel said Monday at the JPMorgan Healthcare Conference. Bancel points out that Pfizer's partnership with the European Union expires at the end of the year, giving Moderna a window to capture a share of the high-volume Covid-19 vaccine market in Europe. If Moderna is able to get European approval for a flu-plus-Covid combo vaccine in 2026, that would also be a positive catalyst for sales growth, he says. The company is also looking to build on partnerships with governments in the United Kingdom, Canada, and Brazil as it looks to drive geographic diversity, Bancel says.(elias.schisgall@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 11:13 ET (16:13 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}